The investment bank said it views atacicept as "largely de-risked, with a line of sight to commercialization starting next year." It added that feedback from Key Opinion Leaders indicates ...

Vera Therapeutics (VERA) announced that it has completed full enrollment in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA ...

Vera Therapeutics, Inc. (NASDAQ:VERA) said on Wednesday that it had completed full enrollment (431 participants) in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA Nephropathy ...

The decline was attributed to new information released by Otsuka regarding its drug sibeprelimab, which is anticipated to be a direct competitor to Vera's atacicept. Analyst Liisa Bayko of ...

Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on April 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 211,250 shares ...

The ORIGIN 3 trial is a randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of atacicept—a recombinant fusion protein targeting B-cell modulators—for ...

“We are grateful for the IgAN community’s strong interest in the clinical development of atacicept that helped drive us towards completing full enrollment in the ORIGIN 3 trial with a total of ...

ORIGIN 3 fully enrolled with 431 participants to assess atacicept in IgAN over 104 weeks Primary data readout on proteinuria reduction expected this quarter from 36-week interim China’s new ...

BRISBANE, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative ...

Vera Therapeutics, Inc. (NASDAQ:VERA) said on Wednesday that it had completed full enrollment (431 participants) in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA Nephropathy (IgAN ...

“We are grateful for the IgAN community’s strong interest in the clinical development of atacicept that helped drive us towards completing full enrollment in the ORIGIN 3 trial with a total of 431 ...